Non-invasively aids in the detection, staging, and monitoring of liver fibrosis for nonalcoholic steatohepatitus (NASH) patients.
Introduction to NASH
Nonalcoholic steatohepatitis (NASH) affects approximately 25 million people in the US.1 In 2019 NASH was the second leading indication, and the indication increasing with the fastest rate, for liver transplantation.2 Currently, biopsy is the gold standard for the diagnosis of NASH. However, biopsy may be subject to sampling problems that can confound the results, in addition to surgical costs, risk, and inconvenience for the patient.
Identifying High-Risk NASH Patients is Imperative
- F3-F4 stage of liver fibrosis has been identified as the most significant independent risk factor for mortality in NASH patients3,4
- NASH-related cirrhosis is becoming a more common indication for liver transplantation3
- Progression of NASH-related liver fibrosis is 2 times faster than nonalcoholic fatty liver disease5